Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Concurrent immunotherapy in SCLC

Kenneth O'Byrne • 31 Jan 2020
BTOG 2020
Lung Cancer Small Cell Lung Cancer Atezolizumab Checkpoint Inhibitors Durvalumab

Kenneth O’Byrne, MD, MB, BCh, BAO, Princess Alexandra Hospital & Queensland University of Technology, Woolloongabba, Australia, discusses trials investigating atezolizumab and durvalumab in the concurrent treatment of small cell lung cancer. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Kenneth O'Byrne

5:55
Checkpoint inhibitor resistance in lung cancer
Kenneth O'Byrne • 30 Jan 2020
3:03
The tumor microenvironment: lung cancer
Kenneth O'Byrne • 30 Jan 2020
2:28
Painting the lung cancer cell picture
Kenneth O'Byrne • 30 Jan 2020
2:34
GioTag: real world data on first-line afatinib followed by osimertinb
Kenneth O'Byrne • 25 Jan 2019

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals